A UK study on hydroxychloroquine will resume, just weeks after being halted.
The trial will see healthcare workers given the anti-malarial drug, and will continue after getting approval to proceed from the UK Medicines Agency.
Dr Siu Ping Lam, Director of Licensing at the MHRA, said: "We have reviewed the University of Oxford’s request to recommence recruitment for the ‘COPCOV’ trial, investigating the use of hydroxychloroquine in the prevention of Covid-19.
SEE ALSO: Medics’ alarm over two towns
"After analysing the additional risk mitigations and consulting the Commission on Human Medicines, we have given the clinical trial the green light to recruit more participants.
"Participant safety is our priority, so we will continue to monitor the trial to ensure ongoing appropriate measures are in place to maintain continued high levels of safety."
The news comes just three weeks after the UK halted the trial after scientists found that there was 'no evidence of benefit' for Covid-19 patients.
Speaking at the time, Professor Peter Horby and Professor Martin Landray, chief investigators of the trial, said: "We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19.
"We have therefore decided to stop enrolling participants to the hydroxychloroquine arm of the RECOVERY trial with immediate effect."
SEE ALSO: Cases rise to 7,188 as number of critically ill patients surges
However, the MHRA received a request from the University of Oxford on 17 June, to recommence recruitment for the controversial trial.
And on 26 June, it was agreed that sufficient measures had been taken to support the safe recruitment of further participants for the trial.
The drugs rose to prominence since Trump said he was taking hydroxychloroquine as a preventive medicine against the virus despite medical warnings about its use.